Stephens Cuts Medifast (NYSE:MED) Price Target to $12.00

Medifast (NYSE:MED) had its price target trimmed by Stephens from $15.00 to $12.00 in a research note issued to investors on Thursday, MarketBeat Ratings reports. The firm currently has an equal weight rating on the specialty retailer’s stock.

Other equities analysts also recently issued reports about the stock. Wall Street Zen upgraded shares of Medifast from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Medifast has a consensus rating of “Reduce” and a consensus target price of $12.00.

Medifast Trading Up 0.1%

MED stock opened at $10.63 on Thursday. The firm has a 50 day moving average of $11.27 and a 200-day moving average of $12.27. The company has a market cap of $116.86 million, a price-to-earnings ratio of -6.22 and a beta of 0.53. Medifast has a 12-month low of $10.10 and a 12-month high of $15.48.

Medifast (NYSE:MED) last released its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.The business had revenue of $75.10 million for the quarter, compared to analysts’ expectations of $71.40 million. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS. Sell-side analysts forecast that Medifast will post 0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Medifast

Institutional investors have recently added to or reduced their stakes in the business. Amundi boosted its stake in Medifast by 43.5% in the 1st quarter. Amundi now owns 30,439 shares of the specialty retailer’s stock worth $398,000 after buying an additional 9,224 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Medifast by 14.5% during the 1st quarter. AQR Capital Management LLC now owns 199,750 shares of the specialty retailer’s stock worth $2,693,000 after acquiring an additional 25,366 shares during the period. Strs Ohio acquired a new stake in shares of Medifast in the first quarter worth approximately $78,000. CWM LLC boosted its position in shares of Medifast by 564.6% in the second quarter. CWM LLC now owns 7,457 shares of the specialty retailer’s stock worth $105,000 after acquiring an additional 6,335 shares during the last quarter. Finally, Allianz Asset Management GmbH purchased a new stake in Medifast in the second quarter valued at approximately $307,000. 95.51% of the stock is currently owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.